Welcome to our dedicated page for Procept Biorobotics SEC filings (Ticker: PRCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Robotic surgery filings can be harder to parse than the technology itself. PROCEPT BioRobotics’ reports weave FDA submissions, multi-center clinical-trial data, and device-revenue details into hundreds of technical pages. If you have ever wondered — where do I find the next PROCEPT BioRobotics quarterly earnings report 10-Q filing or how do I track PROCEPT BioRobotics insider trading Form 4 transactions before new trial results hit — this page removes the guesswork.
Stock Titan blends real-time EDGAR feeds with AI-powered summaries so you can move straight to the numbers that matter. Our engine reads every filing, highlights segment revenue from AquaBeam disposables, flags new international clearances buried in an 8-K, and decodes the proxy statement executive compensation table. Need the PROCEPT BioRobotics annual report 10-K simplified, the latest 8-K material events explained, or PROCEPT BioRobotics SEC filings explained simply? One click shows plain-English takeaways alongside original page numbers.
Professionals rely on the platform to:
- Monitor PROCEPT BioRobotics Form 4 insider transactions real-time, including executive stock transactions Form 4.
- Compare R&D spending trends with revenue growth using our PROCEPT BioRobotics earnings report filing analysis.
- Set alerts for PROCEPT BioRobotics proxy statement executive compensation data ahead of the annual meeting.
- Save hours understanding PROCEPT BioRobotics SEC documents with AI instead of reading 300 pages.
All filings — 10-K, 10-Q, 8-K, S-3, SD and more — arrive seconds after they post, complete with key metrics, risk-factor highlights, and jargon-free summaries. Complex robotics disclosures, simplified.
The filing shows that Antal Rohit Desai, a director of PROCEPT BioRobotics (PRCT), exercised stock options and acquired 26,749 shares on 08/14/2025 at a cash exercise price of $1.33 per share. After the transaction he beneficially owns 35,152 shares in total, including 14,363 shares held indirectly by The 2:22 DNA Trust. The option exercised was fully vested and exercisable, and the exercise was executed for cash. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Desai on 08/15/2025.
Insider purchase reported: The Form 4 shows that Frederic Moll, a director of PROCEPT BioRobotics Corp (PRCT), bought 20,000 shares on 08/13/2025 at a weighted average price of $39.2569 per share. After the transactions, he beneficially owns 863,159 shares. The filing notes the shares were acquired in multiple trades with prices ranging from $38.71 to $39.645 and offers to provide a break‑down on request. The form was signed by an attorney‑in‑fact on 08/14/2025.
Nouri Alaleh, EVP and Chief Legal Officer of PROCEPT BioRobotics (PRCT), exercised stock options and acquired 11,000 shares on 08/14/2025. The exercise was a cash exercise at an exercise price of $4.52 per share for options that are fully vested and exercisable. After the transaction the reporting person beneficially owns 72,473 shares of common stock directly and holds derivative interests corresponding to 11,000 underlying shares, with 54,452 derivative securities beneficially owned following the transaction. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
FAQ
What is the current stock price of Procept Biorobotics (PRCT)?
What is the market cap of Procept Biorobotics (PRCT)?
